Cannabis-based products for medicinal use, known in UK shorthand as CBMPs, have been legal to prescribe in Britain since 1 November 2018. More than seven years on, NHS medical cannabis prescriptions remain a rarity. The vast majority of patients now access these products through private specialist clinics. For investors, operators and policymakers tracking the European cannabis market, the gap between legal status and routine NHS access is the single most consequential feature of the UK landscape.
Background: how the UK arrived at the current framework
The 2018 rescheduling moved CBMPs from Schedule 1 to Schedule 2 of the Misuse of Drugs Regulations, allowing specialist doctors registered on the General Medical Council Specialist Register to prescribe unlicensed cannabis medicines. The change followed two high-profile paediatric epilepsy cases that drew national attention and prompted the Home Secretary to commission a review by the Chief Medical Officer and the Advisory Council on the Misuse of Drugs.
The subsequent guidance from the National Institute for Health and Care Excellence, published on 11 November 2019, set a narrow framework. NICE recommended cannabidiol with clobazam for two rare forms of childhood epilepsy and nabiximols, sold as Sativex, for spasticity in multiple sclerosis. It did not recommend routine NHS prescribing of unlicensed cannabis-based products for chronic pain or for the broader range of indications now treated in the private sector.
The current state of NHS prescribing
In the seven years since rescheduling, NHS prescriptions of unlicensed CBMPs have been reported in single figures. The two licensed products, Epidyolex and Sativex, are prescribed in larger but still modest numbers, and access to Sativex on the NHS varies significantly between integrated care boards. Patients seeking products outside the licensed pathway, including dried cannabis flower and a wider range of oils, are in practice directed to private specialist services.
Several factors explain the gap. NHS commissioners require evidence from randomised controlled trials, and most unlicensed CBMPs do not have that evidence base for the indications for which patients seek them. Specialist clinicians within the NHS face institutional risk in initiating prescriptions for unlicensed medicines without local formulary support. Funding for individual funding requests is rarely granted. And the supply chain for unlicensed CBMPs sits largely outside NHS procurement frameworks.
The result is a two-tier system. NHS access is concentrated in a narrow band of licensed indications. Private access, delivered through specialist clinics regulated by the Care Quality Commission, has expanded rapidly. By the mid-2020s, industry estimates suggested the UK private patient population had grown into the tens of thousands, with a network of clinics, pharmacies and licensed importers servicing the market.
What this means for businesses
For operators, the practical implication is that the UK is a private-pay medical market with regulatory characteristics distinct from any other large European jurisdiction. Companies entering the supply chain must navigate import licensing through the Home Office, Good Manufacturing Practice requirements for finished products, and the unlicensed special obligations that govern how unlicensed medicines are dispensed.
For investors, the gap between NHS and private access is both the constraint on market size and the central thesis for growth. Any meaningful expansion of NHS prescribing, whether through revised NICE guidance, new licensed products, or commissioning policy changes, would shift the addressable market by an order of magnitude. The directionality of clinical evidence, including data from observational studies such as Project Twenty21 led by Drug Science and registry work conducted through specialist clinics, has supported continued private growth without yet producing the randomised trial data NHS commissioners require.
For policymakers, the current settlement raises an equity question. Patients who can pay privately access a treatment that the state has deemed legal but not routinely funded. The Medical Cannabis Clinicians Society and patient advocacy groups have called for guidance reform, NHS pilot programmes and funded clinical trials. The Advisory Council on the Misuse of Drugs has periodically reviewed scheduling, and further policy movement is likely to remain on the agenda through the rest of the decade.
Key considerations and what to watch
Three indicators will determine whether the NHS medical cannabis position shifts materially in the coming years. The first is the trial pipeline. New randomised trial data on cannabis-based products for chronic pain, anxiety and post-traumatic stress disorder, where the largest unmet demand sits, would force a re-examination of NICE guidance.
The second is licensed product approval. A licensed cannabis product addressing a high-prevalence indication, rather than the rare epilepsies and spasticity covered today, would route through normal NHS commissioning rather than the unlicensed special pathway.
The third is the regulatory perimeter. Reviews of cannabis scheduling, prescribing rights, and the role of general practitioners as initiators rather than continuers of treatment would each reduce frictions in the access pathway. For a fuller view of the regulatory environment, see Cannabis Europa’s analysis of the UK cannabis legal framework and the broader European medical cannabis landscape.
The NHS medical cannabis question sits at the intersection of clinical evidence, commissioning policy and patient demand. For senior decision-makers in the UK and European cannabis industry, it remains the most important variable in long-term market sizing. The debate will be a central thread at Cannabis Europa London 2026, where regulators, clinicians and operators meet on 26 and 27 May 2026.